Elephas is developing a technology platform to assess how live tumor cells respond to cancer therapies, with the aim of enabling clinicians to treat cancer patients more effectively. The platform is being developed for use with immunotherapy agents alone and in combination with traditional chemotherapy and targeted therapies. Elephas' mission is to develop innovative cancer diagnostic products and services that enable accurate prediction of clinical treatment outcomes and accelerate drug development, in response to the need for improved diagnostics, novel pharmaceutical therapies, and the shift to patient-centric solutions in healthcare. Despite advances in precision medicine and a significant increase in the number of available therapies, many cancer patients still derive no benefit from their treatment, and Elephas aims to change this by leading the way in changing how clinicians treat cancer patients.